News
Treatment Landscape for Dermatomyositis Is Evolving
After years of inactivity, therapeutic development for dermatomyositis has begun to move forward with several new therapies and therapeutic strategies.
Don’t Hold the JAK (10.9.2026)
On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients.
Can DMARD Doses Be Safely Reduced for RA Patients?
Don't Hold the Biologic or JAK with COVID-19 Vaccination
A randomized clinical trial in inflammatory arthritis arthritis shows that temporarily holding biologic or Janus kinase (JAK) inhibitor therapy at the time of COVID-19 vaccination is not warranted.Predicting and Preventing Psoriatic Arthritis
POETYK PsA-1 - Efficacy and Safety of Deucravacitinib in Psoriatic Arthritis
van der Heijde et al have published the results of the phase 3 POETYK PsA-1 trial demonstrating that deucravacitinib was superior to placebo in clinical responses, patient-reported outcomes, and structural damage inhibition in patients with psoriatic arthritis (PsA).EBR Journal Club: Brepocitinib in Dermatomyositis (VALOR)
The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How great are the benefits and harms? And what didn’t they show me? Feel free to use this in your own journal clubs! This edition: VALOR (brepocitinib in dermatomyositis).Exercise Can Improve Pain
This pooled meta-analyses (n=197,392) shows that exercise reduced pain versus control immediately after the intervention (SMD −0.59; 95% CI −0.65 to −0.53; P0.001). The benefit held across musculoskeletal, inflammatory, neurologic and cancer pain, and for every modality tested.Triple Hormone Receptor Agonist for Treatment of Obesity and Knee Osteoarthritis
The NEJM reports that retatrutide, an investigational incretin agent, was shown to yield up to 25% weight reduction, with subanalyses also showing reduced pain with knee osteoarthritis, and less apnea–hypopnea events in participants with obstructive sleep apnea.Remission – Believe it or Not (10.2.2026)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Petri SLE Pearls: An Update
At the CCR West 2026 conference in Huntington Beach, California, Dr. Michelle Petri updated her Petri Pearls. Some are derived from new data, while others are from her extensive experience caring for patients with systemic lupus erythematosus (SLE).
Ambient AI in Rheumatology Practice: Less Typing or Less Human?
Ambient AI documentation is being adopted as a tool for clinical documentation, with the potential to improve efficiency and patient interaction. This may be particularly well suited to rheumatology, where visits often involve complex, longitudinal histories, multiple high-risk medications, and extensive counseling. Ambient AI also introduces significant risks.The GLP-1 Opportunity Cost in Rheumatology
There is no doubt it is an incredibly exciting time to be tackling obesity-related diseases, like many rheumatic diseases appear to be, to some extent. However, deep down, a part of us must dread adding yet another conversation to a crowded consultation. One of two things has to happen: we either outsource, or get more efficient. Ideally we can do a bit of both.Supervised Physiotherapy Wins after ACL Repair
The Annals of Internal Medicine has shown that chronic knee symptoms following anterior cruciate ligament reconstruction (ACLR) surgery is significantly lessened by a program of physiotherapist-supervised exercise therapy with education compared to single education and self-directed exer
